DYAI
DYADIC INTERNATIONAL INC
$0.6800
0.00%
$24.9M
No data for this timeframe.
Vol
Market Cap$24.9M
Cap SizeNano Cap
Inst. Holders15 funds
Inst. Value$1.4M
Inst. Activity0 buys / 2 sells
Reddit Sentiment42° Neutral
SEC Reports1
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001213809·Prev Close $0.6800
Recent Activity
May 28, 2026
SEC
Dyadic (DYAI) announced a research collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candi
8-K — Impact 4/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
81,665 shares ($67.0K)
Inst.
COMMONWEALTH EQUITY SERVICES, LLC — TRIM
12,579 shares ($10.3K)
Jun 15, 2026
other
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activ
Mar 25, 2026
Press
Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.09 million from $3.50
Impact 5/10
Mar 16, 2026
Press
Dyadic International has entered into an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recom
Impact 5/10
Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$6.00 (Nov 2024)
Current $0.6820
Low $5.00
Median $6.00
High $7.00
2 analysts
$5.00
$7.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jul 8, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 13, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 24, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 3, 2023 | HC Wainwright & Co. | REITERATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▲ +8.3% | $-0.04 — $-0.03 | 39% YoY | 3 |
| Next Q | $-0.03 ▲ +25.0% | $-0.03 — $-0.03 | 50% YoY | 3 |
| Current FY | $-0.10 | $-0.13 — $-0.07 | 58% YoY | 3 |
| Next FY | $0.03 ▲ +233.3% | $-0.08 — $0.17 | 134% YoY | 3 |
Latest Reports
NEUTRAL
8-K
4/10
Dyadic (DYAI) announced a research collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candi
May 28, 2026
MIXED
Press
5/10
Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.09 million from $3.50
Mar 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $761.2K | — |
| BlackRock, Inc. | $225.8K | — |
| VANGUARD FIDUCIARY TRUST CO | $114.4K | — |
| RENAISSANCE TECHNOLOGIES LLC | $67.0K | TRIM |
| HighTower Advisors, LLC | $65.2K | — |
Reddit Sentiment
42°
Neutral
Bearish
Neutral
Bullish
15 institutional holders with $1.4M total value (1,685,086 shares) as of 2026-Q1. Top holders: VANGUARD, BlackRock,, VANGUARD. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 928,233 | $761.2K | 55.1% | — |
| 2 | BlackRock, Inc. | 275,425 | $225.8K | 16.3% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 139,478 | $114.4K | 8.3% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 81,665 | $67.0K | 4.8% | TRIM -44.7% |
| 5 | HighTower Advisors, LLC | 79,469 | $65.2K | 4.7% | — |
| 6 | CITADEL ADVISORS LLC | 72,900 | $59.8K | 4.3% | ADD +35.4% |
| 7 | STATE STREET CORP | 42,550 | $34.9K | 2.5% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 25,925 | $21.3K | 1.5% | — |
| 9 | CAPTRUST FINANCIAL ADVISORS | 15,000 | $12.3K | 0.9% | — |
| 10 | COMMONWEALTH EQUITY SERVICES, LLC | 12,579 | $10.3K | 0.7% | TRIM -44.3% |
| 11 | Vanguard Global Advisers, LLC | 7,385 | $6.1K | 0.4% | — |
| 12 | PNC FINANCIAL SERVICES GROUP, INC. | 4,000 | $3.3K | 0.2% | — |
| 13 | MORGAN STANLEY | 227 | $186.00 | 0.0% | NEAR_EXIT -95.8% |
| 14 | WELLS FARGO & COMPANY/MN | 178 | $146.00 | 0.0% | — |
| 15 | BARCLAYS PLC | 72 | $59.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 147,615 | 81,665 | -44.7% | $67.0K | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 22,579 | 12,579 | -44.3% | $10.3K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 5,427 | 227 | -95.8% | $213.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 47,605 | 165,100 | +246.8% | $194.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 203 | 15 | -92.6% | $18.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 30,976 | 47,605 | +53.7% | $47.1K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 27,132 | 175 | -99.4% | $236.00 | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 167 | 27,132 | +16146.7% | $47.5K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 12,254 | 5,654 | -53.9% | $9.9K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 454 | 12,254 | +2599.1% | $12.7K | 2024-Q3 |
| CITADEL ADVISORS LLC | ADD | 5,844 | 7,911 | +35.4% | $8.2K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
MIXED
5/10
Dyadic International reported its 2025 financial results, showing a decline in total revenue to $3.0
Mar 25, 2026
MIXED
5/10
Dyadic International has entered into an OEM distribution agreement with IBT Bioservices to commerci
Mar 16, 2026
NEUTRAL
4/10
Dyadic International and Fermbox Bio announced the commercial launch of animal-origin-free Recombina
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Nov 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2024. No current recommendation available.
$6.00 mean target (Nov 2024)
$5.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $0.6820 |
| Target Low | $5.00 |
| Target Mean | $6.00 |
| Target Median | $6.00 |
| Target High | $7.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.04 | $-0.03 | 38.9% | +8.3% | — | $0.0B | 1.1% | 3 |
| Next Q 2026-09-30 |
$-0.03 | $-0.03 | $-0.03 | 50.0% | +25.0% | 1↑ 0↓ | $0.0B | 39.6% | 3 |
| Current FY 2026-12-31 |
$-0.10 | $-0.13 | $-0.07 | 58.0% | +0.0% | 1↑ 2↓ | $0.0B | 119.8% | 3 |
| Next FY 2027-12-31 |
$0.03 | $-0.08 | $0.17 | 134.5% | +233.3% | 1↑ 1↓ | $0.0B | 94.7% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.037 | |
| 7d ago | $-0.040 | +0.003 |
| 30d ago | $-0.040 | +0.003 |
| 60d ago | $-0.040 | +0.003 |
| 90d ago | $-0.040 | +0.003 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 3, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Jul 18, 2022 | Dawson James | DOWNGRADE | Buy | Neutral |
| Apr 5, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Dec 17, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
42°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
1 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 15, 2026
other
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
May 19, 2026
other
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
May 13, 2026
earnings
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND
HIGHLIGHTS RECENT COMPANY PROGRESS
May 13, 2026
earnings_calendar
DYAI Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings_calendar
DYAI Q1 2026 Earnings Scheduled — 2026-05-07
Mar 25, 2026
earnings
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
DYADIC ANNOUNCES 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS
Mar 25, 2026
earnings_calendar
DYAI Q4 2025 Earnings After Market Close — 2026-03-25
Mar 16, 2026
contract
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Mar 11, 2026
earnings
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic to Report Year 2025 Financial Results
Mar 4, 2026
contract
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration:
Animal-Origin-Free Recombinant DNase I (RNase-Free)
Mar 2, 2026
other
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Mi